Tuesday, November 12, 2019

U.S. IVD Market Growth to Witness Steady Expansion During 2017 - 2023


In vitro diagnostics (IVD) are laboratory-based analysis performed in in vitro conditions to determine general state of health and presence of diseases, and to assess disease progression and treatment. Infections, cancer, cardiovascular immunological, nephrological, and gastroenterological diseases are diagnosed in an in vitro environment. Evolution of information technology plays an important role in the development of automated techniques.

The U.S. IVD Market was valued at $15,746 million in 2016, and is projected to reach at $20,707 million by 2023, growing at a CAGR of 3.9% from 2017 to 2023. The reagent segment accounted for more than three-fifths share of the total market in 2016.


Increase in geriatric population, rise in disposable income, and high healthcare expenditure in the U.S. drive the market growth. However, unfavorable reimbursement policies and stringent government regulations related to the safety and efficacy of the IVD are expected to restrain the market growth during the forecast period. Ongoing R&D associated with the IVD and increase in awareness of preventive healthcare measures provides huge growth potential for IVD market.

The major players profiled Are:
  • Thermo Fisher Scientific Inc.
  • Alere Inc.
  • Biomerieux
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Becton Dickinson and Company
  • Bio-Rad Laboratories
  • Bayer AG
  • Sysmex Corporation
  • Johnson & Johnson among others.

Based on product type, the reagents segment held the highest market share in 2016, owing to the recent government approval of new novel reagents in the market and wide availability of cost effective and efficient reagents.

Based on technique, the immunodiagnostics segment contributed the highest market share in 2016, owing to the increase in prevalence of chronic and infectious diseases such as diabetes, cancer, & others and rise in awareness of personalized medicine among the population.

Based on application, the infectious diseases segment contributed the highest market share in 2016, owing to the increase in rise in awareness of preventive health measures and increase in adoption of home test kits.


Based on end users, the standalone laboratory segment captured the highest market share in 2016, mainly due to wide availability of skilled professional and complex tests & high-tech infrastructure enabling fast and reliable test results.

Key Findings of the U.S. IVD Market:
  • The reagent segment dominated the market in 2016, and is projected to grow at the 2.9% CAGR.
  • The immunodiagnostics segment accounted for the highest share in 2016.
  • The infectious diseases segment was the major shareholder in the market in 2016.
  • The standalone laboratory segment accounted for the highest share in 2016.
About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
https://mangeshp.kinja.com
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

No comments:

Post a Comment